“几乎每场讨论都会谈到中国”！秀管线、谈合作、见投资人，从医药行业“春晚”看中国创新药产业跃迁

Core Insights - The 44th JPMorgan Global Healthcare Conference highlighted a shift in focus for Chinese biopharmaceutical companies from local innovation to global competitiveness, emphasizing international collaboration and commercialization strategies [1][5]. Group 1: Company Participation and Activities - Hong Kong biopharmaceutical companies were actively engaged at the JPM conference, showcasing their pipelines, discussing collaborations, and meeting with investors [1]. - Alex Zhavoronkov, CEO of Insilico Medicine, noted a change in the nature of interactions, with more emphasis on showcasing drug progress and maintaining long-term relationships rather than just pitching to investors [2]. - Companies like InnoCare Pharma reported substantial dialogues with multinational pharmaceutical firms, indicating a growing interest in their platform technologies and clinical data [3]. Group 2: Trends in Chinese Biopharmaceuticals - The conference saw an increase in discussions around Chinese innovation, with many sessions focusing on how to leverage Chinese pipelines and partnerships [4]. - The participation of Chinese companies has become more organized and impactful, with presentations shifting from conceptual pitches to solid clinical data and international collaboration examples [5]. - The industry is transitioning from a "fast-follow" approach to "global synchronous innovation," with a focus on international recognition of technology platforms [5]. Group 3: Strategic Messaging for Global Markets - Chinese biopharmaceutical companies are encouraged to demonstrate their innovation capabilities and scientific rigor through high-quality clinical data and advanced technology platforms [6][7]. - There is a strong emphasis on global cooperation, positioning Chinese firms as strategic partners in technology transfer and joint development rather than just project recipients [6][7]. - The narrative is shifting from viewing Chinese innovation as a cost advantage to recognizing its value-driven contributions to the global biopharmaceutical landscape [7].